Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clomifene→

Clomifene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
911-45-5
Molecular formula
C26H28ClNO
Molecular weight
406 g/mol
Drug class
Selective oestrogen-receptor modulator (SERM)non-steroidal ovulation stimulant
Mechanism of action
Interacts with oestrogen receptors in the hypothalamus and alters oestrogen feedback, increasing pituitary gonadotrophin output and promoting ovarian follicular maturation and ovulation.
Indications / reported uses
  • Induction of ovulation in appropriately selected anovulatory or oligo-ovulatory women seeking pregnancy; use requires assessment of the cause of infertility and product-specific eligibility

Sources: UK SmPC — Clomifene 50 mg tablets · US DailyMed — Clomid prescribing information · NCI Drug Dictionary

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective oestrogen-receptor modulator (SERM); non-steroidal ovulation stimulant

Mechanism of action

Interacts with oestrogen receptors in the hypothalamus and alters oestrogen feedback, increasing pituitary gonadotrophin output and promoting ovarian follicular maturation and ovulation.

General use cases

  • Induction of ovulation in appropriately selected anovulatory or oligo-ovulatory women seeking pregnancy; use requires assessment of the cause of infertility and product-specific eligibility

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Clomifene Environmental Risk Assessment (ERA) (the Clomifene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.